NASD · Healthcare · Biotechnology · Israel
Scinai Immunotherapeutics Ltd ADR is a micro cap company (market value under $300 million) in the Biotechnology industry.
Scinai Immunotherapeutics Ltd ADR is a biopharmaceutical company developing immunotherapeutic products for treating infectious and autoimmune diseases. The company operates a GMP manufacturing facility in Jerusalem and is developing a pipeline of nanosized antibodies through collaborations for indications including COVID-19, psoriasis, arthritis, and asthma. It possesses drug manufacturing capabilities and clinical development expertise.
From its FY2022 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Scinai Immunotherapeutics Ltd ADR stock.
Not valued: We cannot value this company yet.
We do not publish a value for this company: its filings cover three fiscal years and projecting growth needs four in a row.
134 more in this industry show a wider margin of safety.
We do not publish a verdict on SCNI yet. A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover three fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.
We do not publish one (as of the 2026-10-30 close). A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover three fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.